Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH
NCT02928432Phase 2Completed
- Sponsor
- Spanish National Cancer Research Centre
- Start
- Jun 2013
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexamethasone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Spanish National Cancer Research Centre. Primary endpoint: Percentage of PSA response at 12 months. Started Jun 2013; status: completed.
02
Drugs
dexamethasone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02928432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928432.